2,4,6, 11, 12, CMIT/MIT is not a candidate for The available data on authorised The AS can be used in 2 PT for which 1 1 2 13 substitution. It is classified as a skin products of the MSCAs indicates that the industry declared intention to opt for sensitizer. Some of the opinions were around 20 BPS are currently on the UA CMIT/MIT adopted by simple majority vote (PT2, , market. This number is an underestimate 4, 6, 13) due to the regulatory transition period and missing data. 2,3,4 PHMB is a candidate for substitution. - The AS can be used in 3 PT for the 0 0 1 From the public consultation the industry declared intention to opt for UA comments were that there are currently PHMB AS being reviewed under Reg. (EU) 528/2012 intended for use under the same PTs. 3 The AS is not a candidate for No BPs found in the data made available 0 0 0 Bacillus substitution. by the MSCAs on Bacillus amyloliquefaciens amyloliquefaciens. 6 DBDCB is not a candidate for No interest declared for UA for PT6 0 1 1 DBDCB substitution. 18 Cyromazine is not a candidate for Both in our survey and the AISE/EBPF 0 0 1 substitution. survey the industry reported very low interest in UA for products falling Cyromazine this PT. Only 17% of the products would apply for UA of which only 10% would opt for the BPF option.
CMIT/MIT 2,4,6, 11, 12, 13 CMIT/MIT is not a candidate for substitution. It is classified as a skin sensitizer. Some of the opinions were adopted by simple majority vote (PT2, , 4, 6, 13) The available data on authorised products of the MSCAs indicates that around 20 BPS are currently on the market. This number is an underestimate due to the regulatory transition period and missing data. The AS can be used in 2 PT for which the industry declared intention to opt for UA 1 1 2 PHMB 2,3,4 PHMB is a candidate for substitution. From the public consultation the comments were that there are currently AS being reviewed under Reg. (EU) 528/2012 intended for use under the same PTs. - The AS can be used in 3 PT for the industry declared intention to opt for UA 0 0 1 Bacillus amyloliquefaciens 3 The AS is not a candidate for substitution. No BPs found in the data made available by the MSCAs on Bacillus amyloliquefaciens. 0 0 0 DBDCB 6 DBDCB is not a candidate for substitution. No interest declared for UA for PT6 0 1 1 Cyromazine 18 Cyromazine is not a candidate for substitution. Both in our survey and the AISE/EBPF survey the industry reported very low interest in UA for products falling this PT. Only 17% of the products would apply for UA of which only 10% would opt for the BPF option. 0 0 1